Brainstorm strengthens exosome patent portfolio: receives notice of allowance for u.s. patent covering its platform technology

New york , dec. 3, 2024 /prnewswire/ -- brainstorm cell therapeutics inc. (nasdaq: bcli), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced today that it has received notice of allowance from the u.s. patent & trademark office (uspto) for patent application 16/981,757 which covers its proprietary exosome technology.    the patent describes the composition and method of brainstorm's unique exosomes that are isolated from the secretome of msc-ntf (mesenchymal stem cells that secrete neurotrophic factors).
BCLI Ratings Summary
BCLI Quant Ranking